| Management target | Revenue FY27 |
|---|
| Revenue growth | Deferred supply of 6-7M pens impacts FY27 revenue timing. |
|---|---|
| Margins | Inventory write-downs expected for impacted batches in Q1 FY27. |
| Demand visibility | Strong; management claims demand significantly outstrips current supply capacity. |
| Management confidence | Balanced; transparent about technical failures while committed to resolution. |
Growth
Supply of 6-7 million pens now deferred to late Q3/Q4 FY27; oral Semaglutide remains unaffected.
Outlook
Resumption of commercial supply expected by October/November 2026 (FY27) following successful re-validation of API manufacturing process.
Risks
Process impurity in API scale-up triggers total commercial supply suspension until validation completion; potential market share loss to competitors.
Earnings Call filed with BSE, NSE: DRREDDY. Summary written with AI assistance from the document.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,203.80
- Market cap
- ₹1,00,478 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 31.2×Sector 47.3×
- Promoter holding
- 26.64%+0.01% QoQ
- FII holding
- 20.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Board Meeting Date
Dr. Reddy’s Laboratories will hold a board meeting on October 23, 2026, to approve the standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Reddy's Laboratories Partnership
Dr. Reddy's signed an exclusive distribution agreement with Takeda for Qdenga dengue vaccine in India's private market. No upfront consideration stated; availability expected H1 2027.
Dr. Reddy's Laboratories Price Movement Clarification
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's Laboratories Business Update
Dr. Reddy's Laboratories received two observations from the USFDA following a records assessment of its API manufacturing facility in Jiutepec, Mexico.
Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's Laboratories allotted 375 equity shares to employees upon the exercise of stock options under its ESOP scheme.
Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's Laboratories allotted 4,110 equity shares to employees under its 2002 Employee Stock Option Scheme. The shares rank pari passu with existing equity.